---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024985"
form_type: "8-K"
ticker: null
cik: "0001814140"
company_name: "Apexigen, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T21:00:25.021282+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Apexigen reports positive Phase 2 data for sotigalimab in liposarcoma; mPFS 12.45 mo

## Summary
- Sotigalimab + doxorubicin achieved median PFS of 12.45 months in liposarcoma patients vs historical <5 months for doxorubicin alone.
- Apexigen plans to expand LPS cohort by 10 patients to inform potential Phase 3 registration-enabling trial.
- Favorable safety profile observed; data supports further development in first-line liposarcoma.
- Study is investigator-sponsored trial in collaboration with Columbia University (Gary Schwartz, PI).

## SEC filing metadata
- accession: 0000950170-22-024985
- form_type: 8-K
- cik: 0001814140
- company_name: Apexigen, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 4.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1814140/000095017022024985/0000950170-22-024985-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1814140/000095017022024985/apgn-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024985
- JSON: https://secwatch.observer/filing/0000950170-22-024985.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024985.txt

## Key facts
- Auditor Changes
  Apexigen, Inc. engaged Moss Adams LLP as its auditor.
  - Action: engagement
  - Auditor: Moss Adams LLP
  source text: On November 8, 2022, the Audit Committee approved the engagement of Moss Adams LLP as the Company’s independent registered public accounting firm to audit the Company’s consolidated financial statements for the year ending December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1814140/000095017022024985/0000950170-22-024985-index.htm
- Auditor Changes
  Apexigen, Inc. dismissed Marcum LLP as its auditor.
  - Action: dismissal
  - Auditor: Marcum LLP
  - Successor: Moss Adams LLP
  source text: On November 8, 2022, the audit committee of the board of directors (the “Audit Committee”) of Apexigen, Inc. (the “Company”), dismissed Marcum LLP (“Marcum”), the Company’s independent registered public accounting firm prior to the Company’s business combination transaction that closed on July 29, 2022 (the “Business Combination”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1814140/000095017022024985/0000950170-22-024985-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.